Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 08:56am CET

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.07% 549.8 Delayed Quote.-3.36%
ASTRAZENECA -0.42% 4752 Delayed Quote.-7.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/24ASTRAZENECA : s FluMist wins CDC committee`s backing after two missed years
AQ
02/24ASTRAZENECA : US Panel Says its OK to Use Nasal Spray Flu Vaccine Again
AQ
02/24ASTRAZENECA : Why woodford has not lost his magic touch.
AQ
02/23ASTRAZENECA : Lynparza CHMP for ovarian cancer maintainance
AQ
02/23ASTRAZENECA : Lynparza receives positive EU CHMP opinion in platinum-sensitive r..
PU
02/22ASTRAZENECA : FluMist back on CDC's recommended list of flu vaccines
AQ
02/22ASTRAZENECA : FDA Approves AstraZenecas Lung Cancer Treatment after Rejecting Me..
AQ
02/22ASTRAZENECA : AZ adds another Ionis drug in $330m kidney disease deal
AQ
02/21ASTRAZENECA : It's OK to use nasal spray flu vaccine again, US panel says
AQ
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
More news
News from SeekingAlpha
02/23Arcus Biosciences Files To Raise $100 Million In IPO 
02/23European advisory group backs expanded use for AstraZeneca's Lynparza 
02/233 THINGS IN BIOTECH YOU SHOULD LEARN : February 22, 2018 
02/223 THINGS IN BIOTECH YOU SHOULD LEARN : February 21, 2018 
02/21CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year 
Financials ($)
Sales 2018 22 345 M
EBIT 2018 5 638 M
Net income 2018 2 132 M
Debt 2018 14 217 M
Yield 2018 4,13%
P/E ratio 2018 33,44
P/E ratio 2019 26,40
EV / Sales 2018 4,40x
EV / Sales 2019 4,14x
Capitalization 84 103 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-7.21%84 103
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618